9 Aug. 2019 - As of September 1, 2019, Mr. Lars Green will join Novozymes A/S as EVP and CFO, with responsibility for Finance, IT, Legal and Investor Relations. Lars has worked for Novo Nordisk A/S for 27 years where, most recently, he has headed up Business Services and Compliance, and – as EVP – been part of Novo Nordisk’s Executive Management team. Before assuming his current position, he was head of Finance & Operations for Novo Nordisk in North America. He has been a member of Novozymes’ Board of Directors since 2014 and chairman of the Audit Committee.

Jørgen Buhl Rasmussen, Chairman of the Board of Directors, and CEO Peder Holk Nielsen, comment on the appointment: "We’re very pleased to announce that Lars has accepted the role as EVP and CFO of Novozymes. We’re convinced that Lars is a good match for Novozymes. His ability to set the CFO agenda and engage with the organization will help us deliver on our strategy ‘Better business with biology.’ As a member of the Board of Directors since 2014, Lars has gained a profound knowledge of Novozymes’ business and meets the requirements for the broad array of tasks and responsibilities the CFO position encompasses. Lars brings extensive experience and a good cultural match to Novozymes from his current position as EVP Business Services and Compliance and a member of Executive Management of Novo Nordisk.”

Lars Green comments on the appointment: "I’m very excited to join Novozymes and look forward to developing our strategic plans and delivering on the targets set out in relation to the strategy update together with the rest of the Executive Leadership Team and Novozymes' employees.”

Following his appointment as EVP and CFO, Lars Green has resigned from the Board of Directors with immediate effect, including as chairman of the Audit Committee. The Board of Directors has elected Ms. Agnete Raaschou-Nielsen as the new chair of the Audit Committee with immediate effect.

The changes have no impact on the financial outlook for 2019.